Comprehensive analysis in patients with ulcerative colitis and Crohn's disease treated with biological agents

Comprehensive analysis in patients with ulcerative colitis and Crohn's disease treated with biological agents - Comprehensive analysis in patients with UC and CD treated with biological agents

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053126

Enrollment

200

Registered

2023-12-16

Start date

2019-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who meet the following criteria are enrolled as subjects in this study. 1, Patients who understood the explanations by documentation and oral and signed a consent form to participate in the study. 2, Patients over 18 years old, regardless of gender. 3, UC and CD Patients starting treatment with infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib, filgotinib, upadacitinib, risankizumab, mirikizumab, or carotegrast methyl.

Exclusion criteria

Exclusion criteria: 1, Pregnant women, lactating women, or women who may be pregnant. 2, Patients who are judged by the researchers to be unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
None	—

Countries

Japan

Contacts

Public ContactShunsuke Shibui

Kitasato University Kitasato Institute Hospital Center for Advanced IBD research and Treatment

hnori@insti.kitasato-u.ac.jp03-3444-6161

Outcome results